A disruptive hypoxia activated prodrug for the treatment of resistant cancers: an AI-driven approach

Project Information

TUMAGNOSTIC

Grant agreement ID: 190158311

DOI

10.3030/190158311

Project closed

EC signature date 21 December 2023

Start date 1 January 2024

End date 31 December 2025

Funded under

• The European Innovation Council (EIC)

Total cost

€ 3 517 905,00

EU contribution

€ 2 462 533,50

Coordinated by

CONVERT PHARMACEUTICALS
Belgium

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Intellectual Property Rights

Patent (8)

NOVEL PRODRUGS AND METHODS OF USE THEREOF

Application/Publication number: 13 831349
Date: 2013-08-22
Applicant(s): CONVERT PHARMACEUTICALS

PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY

Application/Publication number: 10 751067
Date: 2010-03-11
Applicant(s): CONVERT PHARMACEUTICALS

KINASE INHIBITOR PRODRUG FOR THE TREATMENT OF CANCER

Application/Publication number: 15 865257
Date: 2015-12-03
Applicant(s): CONVERT PHARMACEUTICALS

PRODRUGS AND MEDICAL USES THEREOF

Application/Publication number: 20 19064112
Date: 2019-05-29
Applicant(s): CONVERT PHARMACEUTICALS

KINASE INHIBITOR PRODRUG FOR THE TREATMENT OF CANCER

Application/Publication number: 15 865257
Date: 2015-12-03
Applicant(s): CONVERT PHARMACEUTICALS

PRODRUGS AND MEDICAL USES THEREOF

Application/Publication number: 20 19064112
Date: 2019-05-29
Applicant(s): CONVERT PHARMACEUTICALS

NOVEL PRODRUGS AND METHODS OF USE THEREOF

Application/Publication number: 13 831349
Date: 2013-08-22
Applicant(s): CONVERT PHARMACEUTICALS

PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY

Application/Publication number: 10 751067
Date: 2010-03-11
Applicant(s): CONVERT PHARMACEUTICALS